A clinical research study for people with atopic dermatitis

The HILLIER study is being done to learn more about whether a study drug works to improve symptoms for people with moderate to severe atopic dermatitis (AD). The study will also look at how safe the study drug is.

The first treatment period will last 16 weeks. In this period, half of the participants will receive a placebo (a medication that looks like the study drug, but has not active ingredient). In the second treatment period of the study, which will last for 36 weeks, all participants will receive the study drug.

Eczema Treatments

You or someone you care for may be able to take part if you/they:

  • Are 12 years of age or older
  • Have been diagnosed with moderate to severe AD
  • Have symptoms even with using creams or lotions.

If you take part, you will be in the study for up to 1 year and 3 months and have 16 visits to the study centre. The study drug and study assessments will be provided at no cost.


  • A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications
  • The aim of this study is to investigate the use of benralizumab as treatment for patients with moderate to severe atopic dermatitis (AD) who remain symptomatic despite treatment with topical medications
  • It is proposed that benralizumab will deplete eosinophils from affected skin, improve symptoms of AD, and improve AD-related quality of life
  • This study is designed to compare the efficacy of treatment with benralizumab versus placebo and compare benralizumab maintenance dosing regimens in the extension period, and is recruiting male and female participants ≥ 12 years of age.

Information regarding study inclusion and exclusion criteria can be found under the heading ‘Eligibility Criteria’ via the link: Benralizumab Study

The following study sites are currently recruiting to the Hillier study; please contact them directly for further information:

Site nameContact nameWebsiteTelephoneLocation
NovatrialsKaren Brennanwww.novatrials.com.au02 4063 3381Newcastle NSW
Premier SpecialistsDr Anna Wilsonwww.dermatologytrialsaustralia.com.au02 9598 5800Kogarah NSW
Royal Melbourne HospitalEmily Bantingwww.thermh.org.au03 9342 4542Melbourne VIC
USC Clinical Trials CentreCatherine Bellwww.usc.edu.au07 5456 3948Sunshine Coast QLD
James Donkin07 5459 4880
Veracity Clinical ResearchMadeleine Supranowiczwww.veracityclinicalresearch.com.au07 3039 1311Brisbane QLD